10/8/2502

~~10269415.7~~ Page 1

scheduled 12/14/04 for 1624

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 18	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS	6	NOV 30	PHAR reloaded with additional data
NEWS	7	DEC 01	LISA now available on STN
NEWS	8	DEC 09	12 databases to be removed from STN on December 31, 2004

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:25:38 ON 14 DEC 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:25:47 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

Patel

<12/2/2004>
12/14/04

STRUCTURE FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7
DICTIONARY FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10782502.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 10:26:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2952 TO ITERATE

100.0% PROCESSED 2952 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:26:25 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Dec 2004 VOL 141 ISS 25
FILE LAST UPDATED: 13 Dec 2004 (20041213/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11099 CAPLUS
DN 136:69597
TI Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
IN Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe
PA USA
SO U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2002002152	A1	20020103	US 2001-833917		20010412
				US 2000-197262P	P	20000414
	US 2004167126	A1	20040826	US 2004-782502		20040219
				US 2000-197262P	P	20000414
				US 2001-833917	A1	20010412

OS MARPAT 136:69597
IT **369355-85-1P 369358-14-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)
RN 369355-85-1 CAPLUS
CN Cyclohexanebutanoic acid, β-amino-α-hydroxy-, hydrazide, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369358-14-5 CAPLUS
CN Cyclohexanebutanoic acid, β-amino-α-hydroxy-, hydrazide, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe,

Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:780840 CAPLUS
DN 135:331197
TI Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
IN Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe Y.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2001079157	A1	20011025	WO 2001-US12274		20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
CA 2406442	AA	20011025	CA 2001-2406442		20010413
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
			WO 2001-US12274	W	20010413
EP 1272456	A1	20030108	EP 2001-925029		20010413
EP 1272456	B1	20041027			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
			WO 2001-US12274	W	20010413
BR 2001007204	A	20040225	BR 2001-7204		20010413
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
			WO 2001-US12274	W	20010413
JP 2004509063	T2	20040325	JP 2001-576759		20010413
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
			WO 2001-US12274	W	20010413
AT 280753	E	20041115	AT 2001-925029		20010413
			US 2000-549995	A	20000414
			US 2001-813008	A	20010321
			WO 2001-US12274	W	20010413

OS MARPAT 135:331197

IT **369355-85-1P 369358-14-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)

RN 369355-85-1 CAPLUS

CN Cyclohexanebutanoic acid, β-amino-α-hydroxy-, hydrazide, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369358-14-5 CAPLUS

CN Cyclohexanebutanoic acid, β-amino-α-hydroxy-, hydrazide, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:25:38 ON 14 DEC 2004)

FILE 'REGISTRY' ENTERED AT 10:25:47 ON 14 DEC 2004
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:26:25 ON 14 DEC 2004
L3 2 S L2

=> s l3 and preventing and angiogenesis
L4 0 L3 AND PREVENTING AND ANGIOGENESIS

=> s angiogenesis and preventing and prevention
L5 83 ANGIOGENESIS AND PREVENTING AND PREVENTION

=> s l5 and hydrazide
L6 1 L5 AND HYDRAZIDE

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793619 CAPLUS
DN 137:294870
TI Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinones and activity as modulators of protein kinases
IN Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho; Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas; Nematalla, Asaad S.
PA Sugen, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081466	A1	20021017	WO 2002-US11001	20020409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-282630P	P 20010409
	US 2003100555	A1	20030529	US 2002-118321	20020409
	US 6797725	B2	20040928		
				US 2001-282630P	P 20010409
	US 2004186161	A1	20040923	US 2004-816957	20040405
				US 2001-282630P	P 20010409
				US 2002-118321	A3 20020409

OS MARPAT 137:294870

GI



I

AB The present invention relates to pyrrole substituted 2-indolinone compds. (shown as I; e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the **prevention** and treatment of protein kinase related cellular disorders such as cancer (no data). In I, R1 and R2 are independently H, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a saturated heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl, -C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alkyl, and R12 is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form -

(CH2)4- or -(CH2)mCO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR14- (R14 is H or alkyl), -S-, or -SO2-; or. (d) -NR15R16 where are R15 and R16 are independently H, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -NR17- (R17 is H or alkyl), -S-, or -SO2-; or R15 and R16 together with the N atom to which they are attached form saturated or unsatd. heterocycloamino;. Although the methods of preparation are not claimed, >80 example prepns. are included, both of I and the unprotected version of I in which the C(O)R6 group has been replaced by H.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT